PT1097922E - Derivados de fenilprostaglandina e 5-tia-omega-substituidos, processo para a sua producao e drogas que os contem como ingrediente activo - Google Patents
Derivados de fenilprostaglandina e 5-tia-omega-substituidos, processo para a sua producao e drogas que os contem como ingrediente activoInfo
- Publication number
- PT1097922E PT1097922E PT99929831T PT99929831T PT1097922E PT 1097922 E PT1097922 E PT 1097922E PT 99929831 T PT99929831 T PT 99929831T PT 99929831 T PT99929831 T PT 99929831T PT 1097922 E PT1097922 E PT 1097922E
- Authority
- PT
- Portugal
- Prior art keywords
- omega
- disease
- syndrome
- expected
- general formula
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000011580 syndromic disease Diseases 0.000 abstract 2
- 230000009885 systemic effect Effects 0.000 abstract 2
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 206010050685 Cytokine storm Diseases 0.000 abstract 1
- 208000013558 Developmental Bone disease Diseases 0.000 abstract 1
- 208000032672 Histiocytosis haematophagic Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000011200 Kawasaki disease Diseases 0.000 abstract 1
- 208000004987 Macrophage activation syndrome Diseases 0.000 abstract 1
- 208000034486 Multi-organ failure Diseases 0.000 abstract 1
- 208000010718 Multiple Organ Failure Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 206010072610 Skeletal dysplasia Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 231100000354 acute hepatitis Toxicity 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000030833 cell death Effects 0.000 abstract 1
- 206010052015 cytokine release syndrome Diseases 0.000 abstract 1
- 238000000502 dialysis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 abstract 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- 201000008383 nephritis Diseases 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 230000035939 shock Effects 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract 1
- 208000020408 systemic-onset juvenile idiopathic arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0033—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP20075298 | 1998-07-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1097922E true PT1097922E (pt) | 2005-06-30 |
Family
ID=16429595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT99929831T PT1097922E (pt) | 1998-07-15 | 1999-07-14 | Derivados de fenilprostaglandina e 5-tia-omega-substituidos, processo para a sua producao e drogas que os contem como ingrediente activo |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6462081B1 (pt) |
| EP (1) | EP1097922B1 (pt) |
| JP (1) | JP3174563B2 (pt) |
| KR (1) | KR100598660B1 (pt) |
| CN (1) | CN1173945C (pt) |
| AT (1) | ATE291013T1 (pt) |
| AU (1) | AU763668B2 (pt) |
| BR (1) | BR9912813B1 (pt) |
| CA (1) | CA2336952C (pt) |
| DE (1) | DE69924258T2 (pt) |
| DK (1) | DK1097922T3 (pt) |
| ES (1) | ES2239448T3 (pt) |
| HU (1) | HUP0204170A3 (pt) |
| NO (1) | NO327781B1 (pt) |
| NZ (1) | NZ509293A (pt) |
| PT (1) | PT1097922E (pt) |
| RU (1) | RU2220135C2 (pt) |
| TR (1) | TR200100623T2 (pt) |
| TW (1) | TWI249520B (pt) |
| WO (1) | WO2000003980A1 (pt) |
| ZA (1) | ZA200100295B (pt) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0200258A2 (hu) | 1999-03-05 | 2002-05-29 | The Procter & Gamble Co. | C16-telítetlen FP-szelektív prosztaglandin analógok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk |
| CA2303060A1 (en) * | 1999-04-14 | 2000-10-14 | United States Gear Corporation | Towed vehicle brake controller |
| KR20020038793A (ko) * | 1999-10-07 | 2002-05-23 | 우에노 도시오 | 발기부전 치료제 |
| TWI247606B (en) | 1999-11-24 | 2006-01-21 | Ono Pharmaceutical Co | Treating agent for osteopenic diseases |
| KR20020067594A (ko) * | 2000-01-05 | 2002-08-22 | 오노 야꾸힝 고교 가부시키가이샤 | 5-티아-ω-치환 페닐-프로스타글란딘 Ｅ-알콜, 이들의제조 방법 및 이들을 유효 성분으로서 함유하는 약제 |
| DK1132086T3 (da) * | 2000-01-31 | 2006-08-28 | Pfizer Prod Inc | Anvendelse af prostaglandin (PGE2) selektive receptor 4 (EP4) agonister til behandling af akut og kronisk nyresvigt |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
| US6586462B2 (en) * | 2000-10-20 | 2003-07-01 | Allergan, Inc. | ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists |
| GB0030541D0 (en) * | 2000-12-14 | 2001-01-31 | Glaxo Group Ltd | Medical uses |
| GB0103269D0 (en) | 2001-02-09 | 2001-03-28 | Glaxo Group Ltd | Napthalene derivatives |
| EP1408961B1 (en) | 2001-07-16 | 2007-07-11 | F. Hoffmann-La Roche Ag | 2 pyrrolidone derivatives as prostanoid agonists |
| CN1893977B (zh) * | 2001-07-23 | 2012-12-05 | 小野药品工业株式会社 | 以ep4激动剂为活性成分的治疗与骨质损失有关的疾病的药物 |
| HU230421B1 (hu) * | 2001-07-23 | 2016-05-30 | Ono Pharmaceutical Co., Ltd | Csonttömegveszteséggel kapcsolatos betegségek kezelésére adható, EP4 agonistát tartalmazó gyógyászati készítmények és hatóanyagként alkalmazható vegyületek |
| JP4529119B2 (ja) * | 2001-08-09 | 2010-08-25 | 小野薬品工業株式会社 | カルボン酸誘導体化合物およびその化合物を有効成分として含有する薬剤 |
| JP2003078830A (ja) * | 2001-09-03 | 2003-03-14 | Sony Corp | デジタル放送受信装置および通信情報伝送方法 |
| WO2003030911A1 (en) * | 2001-10-08 | 2003-04-17 | Medical Research Council | Use of prostaglandin e synthase inhibitors, or ep2 or ep4 receptor antagonists, in the treatment of a pathological condition of the uterus |
| WO2003037373A1 (en) * | 2001-10-31 | 2003-05-08 | Medical Research Council | Use of an ep2 or ep4 receptor antagonist and/or a cox-1 inhibitor for treating cervical cancer |
| WO2003037348A1 (en) * | 2001-10-31 | 2003-05-08 | Medical Research Council | Antagonists of prostaglandin receptors ep2 and/or ep4 for the treatment of dysmenorrhea and menorrhagia |
| WO2003041717A1 (fr) * | 2001-11-12 | 2003-05-22 | Ono Pharmaceutical Co., Ltd. | Preparation pelliculaire persistante pour administration localisee contenant un derive de prostaglandine |
| AU2003209571A1 (en) * | 2002-03-18 | 2003-09-29 | Pfizer Products Inc. | Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension |
| GB0208785D0 (en) * | 2002-04-17 | 2002-05-29 | Medical Res Council | Treatment methtods |
| US20050239872A1 (en) * | 2002-06-06 | 2005-10-27 | Xavier Billot | 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma |
| AU2003254850B2 (en) * | 2002-08-09 | 2008-05-15 | Fumie Sato | Antipruritic agent |
| US7737182B2 (en) | 2002-08-09 | 2010-06-15 | Taisho Pharmaceutical Co., Ltd. | Pharmaceuticals for xerosis |
| EP1563846B1 (en) | 2002-10-10 | 2012-08-29 | Ono Pharmaceutical Co., Ltd. | Endogenous repair factor production promoters |
| JP4477504B2 (ja) * | 2002-11-13 | 2010-06-09 | 大正製薬株式会社 | 鎮痒剤 |
| JPWO2004069788A1 (ja) * | 2003-02-07 | 2006-05-25 | 小野薬品工業株式会社 | カルボン酸化合物 |
| US7855226B2 (en) * | 2003-02-11 | 2010-12-21 | Allergan, Inc. | Treatment of inflammatory bowel disease |
| US7276531B2 (en) | 2003-03-03 | 2007-10-02 | Applied Research Systems Ars Holding N.V. | G-lactam derivatives as prostaglandin agonists |
| AU2004261397A1 (en) | 2003-07-18 | 2005-02-10 | Laboratoires Serono Sa | Hydrazide derivatives as prostaglandin receptors modulators |
| CN1946391A (zh) * | 2004-04-20 | 2007-04-11 | 辉瑞产品公司 | 包含α－2－δ配体的组合 |
| JPWO2006016695A1 (ja) * | 2004-08-10 | 2008-05-01 | 小野薬品工業株式会社 | Ｅｐ４アゴニストを含有してなる高カリウム血症の予防および／または治療剤 |
| WO2006016689A1 (ja) * | 2004-08-10 | 2006-02-16 | Ono Pharmaceutical Co., Ltd. | Ｅｐ４アゴニストを含有してなる下部尿路系疾患の予防および／または治療剤 |
| EP1805139A2 (en) * | 2004-10-26 | 2007-07-11 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
| JPWO2006075690A1 (ja) * | 2005-01-14 | 2008-06-12 | 小野薬品工業株式会社 | 安定な医薬組成物 |
| KR20080000647A (ko) | 2005-04-28 | 2008-01-02 | 오노 야꾸힝 고교 가부시키가이샤 | 경피 흡수 제제 |
| GB0524103D0 (en) | 2005-11-26 | 2006-01-04 | Medical Res Council | Healing |
| US7511168B2 (en) | 2006-01-18 | 2009-03-31 | Shih-Yi Wei | Processes and intermediates for the preparations of prostaglandins |
| UY30121A1 (es) | 2006-02-03 | 2007-08-31 | Glaxo Group Ltd | Nuevos compuestos |
| KR20090075864A (ko) | 2006-10-26 | 2009-07-09 | 오노 야꾸힝 고교 가부시키가이샤 | 첨부제 |
| KR20090089868A (ko) | 2006-12-15 | 2009-08-24 | 글락소 그룹 리미티드 | Ｅｐ４ 수용체 작동제로서 벤즈아미드 유도체 |
| US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
| WO2008136519A1 (ja) | 2007-05-08 | 2008-11-13 | National University Corporation, Hamamatsu University School Of Medicine | Ｅｐ４アゴニストを含有してなる細胞傷害性ｔ細胞の活性化剤 |
| GB0721611D0 (en) | 2007-11-02 | 2007-12-12 | Glaxo Group Ltd | Novel compounds |
| US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
| CA2739571A1 (en) | 2008-10-29 | 2010-08-26 | Aerie Pharmaceuticals, Inc. | Amino acid salts of prostaglandins |
| US8637558B2 (en) | 2008-12-30 | 2014-01-28 | Industry-Academic Cooperation Foundation, Chosun University | Thiazolidinedione derivative and use thereof |
| CA2929545C (en) | 2009-05-01 | 2019-04-09 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
| MX2013001227A (es) * | 2010-07-30 | 2013-04-24 | Allergan Inc | Compuestos y metodos para reparacion de piel. |
| US8697057B2 (en) | 2010-08-19 | 2014-04-15 | Allergan, Inc. | Compositions and soft tissue replacement methods |
| US20120142684A1 (en) * | 2010-12-02 | 2012-06-07 | Allergan, Inc. | Compounds and methods for skin repair |
| AU2012217630A1 (en) | 2011-02-17 | 2013-09-05 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| EP2678022A2 (en) | 2011-02-23 | 2014-01-01 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| EP2814482A1 (en) | 2012-02-16 | 2014-12-24 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| WO2013123272A1 (en) | 2012-02-16 | 2013-08-22 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| WO2013123274A1 (en) | 2012-02-16 | 2013-08-22 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| WO2013123275A1 (en) | 2012-02-16 | 2013-08-22 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| JP2015522528A (ja) | 2012-05-09 | 2015-08-06 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 慢性閉塞性肺疾患の予防または治療方法および医薬組成物 |
| EP2874620B1 (en) | 2012-07-19 | 2016-10-12 | Cayman Chemical Company, Incorporated | Difluorolactam compositions for ep4-mediated osteo related diseases and conditions |
| ES2733998T3 (es) | 2012-10-29 | 2019-12-03 | Cardio Incorporated | Agente terapéutico específico de enfermedad pulmonar |
| WO2014144610A1 (en) | 2013-03-15 | 2014-09-18 | Cayman Chemical Company, Inc. | Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions |
| CN109528721B (zh) | 2013-03-15 | 2021-10-01 | 爱瑞制药公司 | 联合治疗 |
| WO2015009991A2 (en) | 2013-07-19 | 2015-01-22 | Cayman Chemical Company, Inc. | Methods, systems, and compositions for promoting bone growth |
| WO2015056504A1 (ja) | 2013-10-15 | 2015-04-23 | 小野薬品工業株式会社 | 薬剤溶出性ステントグラフト |
| US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
| JP6907319B2 (ja) | 2016-08-31 | 2021-07-21 | アエリエ ファーマシューティカルズ インコーポレイテッド | 眼科用組成物 |
| AU2018243687C1 (en) | 2017-03-31 | 2020-12-24 | Alcon Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
| WO2020056345A1 (en) | 2018-09-14 | 2020-03-19 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58198466A (ja) | 1982-05-12 | 1983-11-18 | Teijin Ltd | ５−チアプロスタグランジン類およびその製造法 |
| JPH072711B2 (ja) | 1986-09-24 | 1995-01-18 | 帝人株式会社 | プロスタグランジンｅ▲下１▼誘導体の製造法 |
| EP0386901A1 (en) | 1989-02-20 | 1990-09-12 | Ono Pharmaceutical Co., Ltd. | Novel 5-hetero-6-oxo-PGE derivatives |
| JPH03223244A (ja) * | 1989-02-20 | 1991-10-02 | Ono Pharmaceut Co Ltd | ５―ヘテロ―６―オキソ―ｐｇｅ誘導体、それらの製造方法およびそれらを含有する薬剤 |
| JP3579448B2 (ja) * | 1993-12-29 | 2004-10-20 | 大正製薬株式会社 | プロスタグランジン誘導体、その塩およびその使用 |
-
1999
- 1999-07-09 TW TW088111637A patent/TWI249520B/zh not_active IP Right Cessation
- 1999-07-14 PT PT99929831T patent/PT1097922E/pt unknown
- 1999-07-14 JP JP2000560089A patent/JP3174563B2/ja not_active Expired - Fee Related
- 1999-07-14 HU HU0204170A patent/HUP0204170A3/hu unknown
- 1999-07-14 BR BRPI9912813-6A patent/BR9912813B1/pt not_active IP Right Cessation
- 1999-07-14 DK DK99929831T patent/DK1097922T3/da active
- 1999-07-14 AU AU46518/99A patent/AU763668B2/en not_active Ceased
- 1999-07-14 KR KR1020017000093A patent/KR100598660B1/ko not_active IP Right Cessation
- 1999-07-14 DE DE69924258T patent/DE69924258T2/de not_active Expired - Lifetime
- 1999-07-14 CN CNB998097039A patent/CN1173945C/zh not_active Expired - Fee Related
- 1999-07-14 NZ NZ509293A patent/NZ509293A/en not_active IP Right Cessation
- 1999-07-14 RU RU2001101470/04A patent/RU2220135C2/ru not_active IP Right Cessation
- 1999-07-14 CA CA002336952A patent/CA2336952C/en not_active Expired - Fee Related
- 1999-07-14 TR TR2001/00623T patent/TR200100623T2/xx unknown
- 1999-07-14 ES ES99929831T patent/ES2239448T3/es not_active Expired - Lifetime
- 1999-07-14 AT AT99929831T patent/ATE291013T1/de active
- 1999-07-14 EP EP99929831A patent/EP1097922B1/en not_active Expired - Lifetime
- 1999-07-14 US US09/720,675 patent/US6462081B1/en not_active Expired - Fee Related
- 1999-07-14 WO PCT/JP1999/003798 patent/WO2000003980A1/ja not_active Application Discontinuation
-
2001
- 2001-01-10 ZA ZA200100295A patent/ZA200100295B/en unknown
- 2001-01-12 NO NO20010213A patent/NO327781B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NO327781B1 (no) | 2009-09-21 |
| NO20010213D0 (no) | 2001-01-12 |
| DE69924258D1 (de) | 2005-04-21 |
| JP3174563B2 (ja) | 2001-06-11 |
| KR20010053386A (ko) | 2001-06-25 |
| NZ509293A (en) | 2003-05-30 |
| AU763668B2 (en) | 2003-07-31 |
| BR9912813B1 (pt) | 2010-11-30 |
| DE69924258T2 (de) | 2006-01-26 |
| BR9912813A (pt) | 2001-05-02 |
| EP1097922B1 (en) | 2005-03-16 |
| TR200100623T2 (tr) | 2001-06-21 |
| AU4651899A (en) | 2000-02-07 |
| CA2336952C (en) | 2009-09-15 |
| DK1097922T3 (da) | 2005-05-30 |
| ES2239448T3 (es) | 2005-09-16 |
| HUP0204170A2 (hu) | 2003-04-28 |
| ATE291013T1 (de) | 2005-04-15 |
| CN1173945C (zh) | 2004-11-03 |
| EP1097922A4 (en) | 2003-02-12 |
| WO2000003980A1 (fr) | 2000-01-27 |
| EP1097922A1 (en) | 2001-05-09 |
| CA2336952A1 (en) | 2000-01-27 |
| TWI249520B (en) | 2006-02-21 |
| NO20010213L (no) | 2001-03-15 |
| CN1312796A (zh) | 2001-09-12 |
| ZA200100295B (en) | 2002-07-10 |
| KR100598660B1 (ko) | 2006-07-13 |
| US6462081B1 (en) | 2002-10-08 |
| RU2220135C2 (ru) | 2003-12-27 |
| HUP0204170A3 (en) | 2005-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1097922E (pt) | Derivados de fenilprostaglandina e 5-tia-omega-substituidos, processo para a sua producao e drogas que os contem como ingrediente activo | |
| BR0314186A (pt) | Derivados de pirimidinona como agentes terapêuticos contra processos inflamatórios, isquêmicos e remodeladores, agudos e crÈnicos | |
| EA200200662A1 (ru) | Никотинамидные бензоконденсированные гетероциклические производные, полезные в качестве селективных ингибиторов pde4-изозимов | |
| DE60140456D1 (de) | Aza heterocyclische derivate und ihre therapeutische verwendung | |
| HRP20050663A2 (en) | Malonamide derivatives as gamma-secretase inhibitors | |
| BR9912562A (pt) | Derivados de pirazol substituìdos condensados com anéis heterocìclicos com seis elementos | |
| FR2874016B1 (fr) | Nanoparticules de derives de la gemcitabine | |
| ES2076226T3 (es) | Utilizacion de trifluorometilfeniltetrahidropiridinas para la preparacion de medicamentos destinados para combatir las alteraciones ansio-depresivas. | |
| EP1258473A4 (en) | BENZOIC ACID DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL PRODUCT CONTAINING SUCH DERIVATIVES AS ACTIVE INGREDIENT | |
| IT1256320B (it) | Derivati eterociclici | |
| ATE479675T1 (de) | Wasserlösliche thalidominderivate | |
| ES2247060T3 (es) | Producto que comprende un inhibidor de la transduccion de las señales de las proteinas g heterotrimericas en asociacion con un agente antihipertensor para una utilizacion terapeutica en el tratamiento de la hipertension arterial. | |
| HUP9601526A2 (hu) | Véralvadásgátló hatású peptidil-arginin-aldehid-származékok és a vegyületeket tartalmazó gyógyszerkészítmények | |
| DE10299023I1 (de) | Antineoplastisch wirkender und den Antineoplastischen effekt Verstaerkender Wirkstoff | |
| IL59507A (en) | 5-(10-9)abeo-6-methylergoline derivatives,their preparation and pharmaceutical compositions containing them | |
| DK270889A (da) | Cytostatisk virksomme anthracyclinderivater, deres fremstilling og anvendelse | |
| JP2006503049A5 (pt) | ||
| DE69932441D1 (de) | Cyanoiminochinoxalin-derivate | |
| DK200300274A (da) | Behandling af brandsår eller forbrændinger | |
| HUP9601527A2 (hu) | Véralvadásgátló hatású peptid-aldehid-származékok és a vegyületeket tartalmazó gyógyszerkészítmények | |
| DE60327249D1 (de) | Anthranilsäureamide und ihre pharmazeutische verwendung | |
| IT1271009B (it) | Derivati del benzopirano e del benzotiopirano attivi sul sistema cardiovascolare | |
| ATE307131T1 (de) | Phenanthrolin-7-onderivate und ihre therapeutische verwendung | |
| ATE252089T1 (de) | Polyhydroxyalkylpyrazine derivate,deren herstellung und diese enthaltende arzneimitteln | |
| RU99105304A (ru) | Инъекционная форма препарата, проявляющего противоишемическую активность |